Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast

Core Insights - Beyond Air, Inc. is set to report its financial results for the third fiscal quarter ended December 31, 2025, on February 13, 2026 [1] - The management team will host a conference call and webcast at 8:00 AM Eastern Time on the same day [1] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to enhance the lives of patients with respiratory illnesses, neurological disorders, and solid tumors [3] - The company has received FDA approval and CE Mark for its first system, LungFit PH, aimed at treating term and near-term neonates with hypoxic respiratory failure [3] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] Research and Development - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of NO with a proprietary delivery system to target specific solid tumors in pre-clinical studies [4]